|Year : 2013 | Volume
| Issue : 1 | Page : 19-26
Effect of Casilan® on 13 C-caffeine metabolism in overnight-fasted healthy Nigerian children
Kazeem A Oshikoya1, Ken Smith2
1 Department of Child Health, Medical School in Derby, University of Nottingham, United Kingdom
2 Department of Clinical Physiology, Medical School in Derby, University of Nottingham, United Kingdom
|Date of Web Publication||22-Feb-2013|
Kazeem A Oshikoya
Academic Division of Child Health, Medical School in Derby, University of Nottingham, Royal Derby Hospital, Uttoxeter Road, Derby DE22 3DT
Source of Support: KAO is a postgraduate research student at the University of Nottingham, being jointly sponsored by the Lagos State Government and the Lagos State University,, Conflict of Interest: None
| Abstract|| |
Objective: To determine the effect of Casilan® on 13 C-caffeine metabolism in healthy Nigerian children. Materials and Methods: Twelve healthy Nigerian children (male: six, female: six) aged 3-8 years were studied on three occasions. After an overnight fast, the children were studied after ingesting Casilan® only (Week 1). They were restudied after ingesting 3 mg/kg of labeled caffeine only (Week 2), and further re-studied after ingesting both Casilan® and labeled caffeine (Week 3). Breath samples were collected by blowing via a straw into an exentainer bottle. The cumulative percentage of 13 C-caffeine exhaled as 13 CO 2 was measured over 2 h. Results: The time courses of 13 C-enrichments in exhaled CO 2 for all the children, after they had ingested labeled caffeine only and after they had ingested both Casilan® and labeled caffeine, were identical. There was a gradual rise and peak of the enrichments at about 60-75 min, followed by a gradual fall (II) or a plateau (III). Contrarily, the time course of 13 C-enrichments for all the children was consistently low and stable after they had ingested Casilan® only (I). The mean values of cumulative percent 13 C-doses recovered in the CO 2 exhaled over a 2-h period, after ingesting labeled caffeine only (8.59 ± 1.10 δ%/mg) and after ingesting both Casilan® and labeled caffeine (8.58 ± 1.33 δ%/mg), were identical, with no statistically significant difference (P = 0.972). This suggests that Casilan® did not affect the CYP1A2 metabolic pathway. Conclusions: Casilan® is a safe, reliable and quantitative food supplement for overnight-fasted children undergoing caffeine breath test.
Keywords: CYP1A2 metabolizing enzyme, food supplement, healthy children, labeled caffeine
|How to cite this article:|
Oshikoya KA, Smith K. Effect of Casilan® on 13 C-caffeine metabolism in overnight-fasted healthy Nigerian children. J Pharmacol Pharmacother 2013;4:19-26
|How to cite this URL:|
Oshikoya KA, Smith K. Effect of Casilan® on 13 C-caffeine metabolism in overnight-fasted healthy Nigerian children. J Pharmacol Pharmacother [serial online] 2013 [cited 2021 Dec 1];4:19-26. Available from: http://www.jpharmacol.com/text.asp?2013/4/1/19/107648
| Introduction|| |
The concept that blood, urine and other body fluids and tissues can be collected and analyzed to yield information for diagnosis of disease states or to monitor disease progression and/or therapy is the foundation of modern medicine.  However, advanced tracer technology with application of stable isotopes in humans has enabled the noninvasive observation of metabolic processes and the assessment of enzyme activities, organ functions and transport processes in vivo.  The stable isotope technique, particularly the use of 13 C-breath tests for diagnostic purposes, has remarkably enriched the gastroenterological diagnostic spectrum and allowed the study of effect of diseases on drug metabolism and drug interaction in children. 
The majority of 13 C-breath tests performed in children and adults involved oral administration of 13 C-labeled substrate to the subject on an empty stomach.  The precision of CO 2 breath test, using 13 C-substrate, is affected by natural fluctuations in the ratio of 13 C/ 12 C in the expired CO 2 .  Most of the natural food substances (carbohydrates, proteins and lipids) and their products contain a varying low proportion of 13 C, which may increase 13 CO 2 in breath tests.  The natural fluctuations of 13 C/ 12 C ratio are increased if the subject had eaten either immediately before or during the breath test.  Also, a meal before or during the breath test would increase the basal metabolic rate, resulting in an overestimation of the predicted resting carbon dioxide production rate (VCO 2 ).
Caffeine breath test (CBT) involves the use of a nonradioactive stable isotope ( 13 C on the 3-methyl group of caffeine). The labeled caffeine is given orally and undergoes 3-N-demethylation, which is a cytochrome P-450-dependent reaction (CYP1A2). After N-demethylation, the labeled methyl group enters the carbon pool as it is converted to formaldehyde, formate and bicarbonate. The bicarbonate is exhaled as carbon dioxide and the exhaled labeled 13 CO 2 correlates with CYP1A2 activity. 
The subjects for 13 C-breath tests are investigated at rest in a sitting position.  Increased physical activity during the breath test would affect endogenous CO 2 production.  Breath samples are collected over a 2-6 h period, depending on the 13 C-substrate administered. Children may rarely be able to sit for this length of time and may rarely fast for the duration of the test; thus, their energy expenditure may likely be above the resting values. Using the resting VCO 2 to calculate the proportion of 13 C-substrate recovered in breath (percentage dose recovered [PDR]), which is the area under the curve of the rate of appearance of labeled CO 2 (PDR/h) against time, may underestimate the true recovery of 13 C in breath CO 2 . 
PDR is a function of breath CO 2 enrichment, VCO 2 and the amount and enrichment of the ingested 13 C-substrate.  A resting value of VCO 2 is usually assumed in many 13 C-breath tests. A predicted value of resting VCO 2 of 300 mmol/(BSA·h),  where body surface area (BSA) = 0.024265 · W 0.5378 · H 0.3964 (W means body weight in kg and H is the body height in cm),  is widely used in many 13 C-breath tests. The BSA equation takes into account the variation of VCO 2 with body size and allows the same value to be assumed in subjects of all ages and size. Resting VCO 2 was also predicted from basal metabolic rate, which was a function of age, gender, height and weight using the Schofield equations  and assuming a respiratory quotient (RQ) of 0.85.  However, most researchers found this method to be inaccurate for young children when compared with the method of Shreeve et al. 
Slater et al.  have raised concern for the accuracy and reliability of the available methods of estimating the predicted values of resting VCO 2 in children. They estimated the total (nonresting) VCO 2 in adults and children during 13 C-breath tests using smoothed and raw heart rates with two nonlinear functions (sigmoid and third-order polynomial equations [x = [a/(1 + e -(y-b)/c)] + d], where x is VCO 2 , y is heart rate and a, b, c and d are constants: a is the amplitude, b is the center, c is the width of the curve and d is an offset, theoretically equivalent to resting metabolic rate). Slater et al.  reported that their method was more accurate and precise in estimating the total VCO 2 in adults and children thus improving the accuracy of calculated PDR in 13 C-breath tests. However, this method has not been validated by other studies and is yet to gain popularity in 13 C-breath tests in children. Moreover, facilities for the heart rate calibration procedure may not be readily available in resource-poor countries where 13 C-breath tests may be useful as noninvasive methods for pediatric pharmacological research in malnourished children.
Previous studies in children involving the use of CBT have shown that children tolerated overnight fasting and the 2-h period for breath samples collection.  Also, physical activities were minimized by engaging the children in fun activities and collecting samples in a sitting position.  These further explain the reasons for the popularity of the methods of Shreeve et al.  and Schofield  for estimating total VCO 2 in CBT in children.
Nutritional deficiency is a major problem of malnourished children; thus, making these children fast over the 2-h period for CBT may not be feasible, for obvious ethical reasons. A low carbohydrate diet is suggested when fasting is not feasible in the pediatric subjects.  Casilan® is a bland high-quality protein powder derived from milk. It is very low in fat and carbohydrate (both less than 1%).  It contains no added sugar, artificial sweeteners, colors, flavors or preservatives, making it an ideal supplement to many drinks and foods to boost the protein content without altering the flavor. A knowledge gap exists on the effect of food supplement on the proportion of 13 C-substrate recovered in breath CO 2 during CBT study in children.
The use of Casilan® as a food supplement in 13 C-CBT to address the unethical issues surrounding fasting of pediatric subjects has not yet been determined. The aim of this study was to determine the effect of Casilan® as a food supplement on 13 C-caffeine metabolism in overnight-fasted healthy children in Nigeria.
| Materials and Methods|| |
Twelve healthy children (six male, six female) were recruited at the general pediatric outpatient clinic, General Hospital, Ikorodu in Lagos, Nigeria. A sample size of 12 subjects has a power of 90%, assuming a difference of 2% in the mean ± SD score of the 2-h percentage cumulative 13 C from the baseline to 1 week of re-study, and the sample size is appropriate for this study at the 5% level of significance.  Subjects were included if they were less than 12 years old and clinically fit after medical examination. The subjects were excluded if they were on regular medication, had hearing impairment, cerebral palsy, elevated blood pressure, abnormal renal or liver function or reported any cardiovascular, respiratory or gastrointestinal disease. The Ethics Committee of the Lagos State Health Service Commission approved the study. The parent of each subject ≤6 years gave written informed consent for their child to participate in the study. Each subject above 6 years gave assent and their parents as well gave written informed consent to participate in the study.
An appointment was given to each of the subjects for 08:00 h on different days between Mondays and Fridays. Subjects abstained from caffeine-containing products for 24 h before the study was commenced. They also fasted overnight and did not take anything orally on the appointment days. On the days of the study, each subject was attended to in a private consulting room in the presence of one of the parents. Body weight was measured (to 0.1 kg) using Seca scales (model 707; Seca Ltd., Birmingham, UK), with the subjects wearing only underpants. Height was measured (to within 1 mm) using a Holtain standiometer (Holtain, Crymych, Dyfed, UK), with the subjects barefoot. Subjects were considered normal if their weight for age and weight for height z-score were ±3 SD of the WHO child growth chart standards. , Vital signs including blood pressure, heart and respiratory rates and temperature were recorded and monitored throughout the study.
The study involved subjects sitting quietly for half an hour before and throughout the CBT in order to minimize physical activities that can influence endogenous CO 2 production and may affect CBT results. In a previous CBT study in adults, normal healthy subjects were re-studied after approximately 1 week.  Our subjects were therefore studied on three occasions at a weekly interval. The first study involved subjects ingesting Casilan® only (study I), made into a cream, at 09:00 h, calculated as one-twelfth of the Recommended Dietary Allowance of calories (RDA: children 3-6 year old [90 kcal/kg], children 7-10 years old [70 kcal/kg]).  Paired breath samples were collected during normal expiration at -20, -10 and -1 min prior to Casilan® (predose samples) and after Casilan® ingestion (postdose samples) at 15-min intervals over a 2-h period. Breath samples were collected by getting each child to blow via a straw into an exentainer bottle.
The second study involved subjects ingesting 3 mg/kg of [3-methyl- 13 C] caffeine (99% 13 C) (study II) at 09:00 h. The caffeine was obtained in powder form from Cambridge Isotope Laboratories (Cambridge, MA, USA). Each sample of the caffeine was dissolved in 10 mL of sterile water and mixed with sugar-free squash to mask its bitter taste, followed by a 20 mL water wash of the container. The quantity of caffeine consumed was approximately equivalent to the amount present in a coke drink. Paired breath samples were collected during normal expiration at -20, -10 and -1 min prior to caffeine (predose samples) and after caffeine ingestion (postdose samples) at 15-min intervals over a 2-h period. Subjects were observed for signs of caffeine toxicity with detailed symptom assessment, while blood pressure and respiratory and heart rates were monitored every half an hour during testing.
The third study involved subjects ingesting Casilan® cream, calculated as one-twelfth of the RDA of calories,  about half an hour prior to caffeine administration (study III). Caffeine administration and breath sample collection were according to the protocol explained earlier. The breath samples were stored in the exentainer bottles for 12 weeks before being couriered to the Clinical Physiology Laboratory of the Medical School in Derby, University of Nottingham, for analysis.
13 C enrichment of breath CO 2 was determined by continuous-flow isotope ratio mass spectrometry  using a SerCon-Automated Breath Carbon Analyser (CF-IRMS) (Europa Hydra; SerCon Ltd, Crewe, UK). Ten milliliter aliquots of breath samples were injected automatically into the analyzer where they were dried and resolved from nitrogen and oxygen by gas chromatography. The purified CO 2 was then passed, using helium as a carrier, into an electron impact ion source of the isotope ratio mass spectrometer. The ion beams at 44, 45 and 46 m/z were monitored continuously and used to evaluate 13 C enrichment of CO 2 , with reference to a 2% CO 2 /98% N 2 gas supply, which had been calibrated against a bicarbonate standard of known 13 C enrichment. Duplicate analyses of each breath sample were performed.
Calculations and statistical analysis
13 C-enrichment of exhaled CO 2 was converted from delta units to atom percent using the accepted atom fraction of the international bicarbonate standard.  13 C-enrichment was expressed as atom % 13 C excess by subtracting the average predose enrichment from each postdose measurement. Cumulative 13 CO 2 output was calculated by averaging the measured 13 C-enrichment of the eight breath samples taken during the first 2 h following administration of the 13 C-caffeine dose and multiplying this by the average output CO 2 (VCO 2 ) over this period (assumed to be 300 mmol/[BSA· h]). , This was expressed as a percentage of the caffeine dose.
The subjects were compared after ingesting Casilan® or labeled caffeine only, and after ingesting both Casilan® and caffeine by using a Student's paired t-test at a P < 0.05 significant level. Spearman's rank correlation, r s , was used to determine the correlation between age, weight or height of the children, and the cumulative percent 13 C-caffeined dose exhaled in 2 hr carbon dioxide in each study.
| Results|| |
The average 13 C-enrichment for the 12 children was calculated at each time the breath samples were collected over a 2-h study period. The average 13 C-enrichments were determined for the children after they had ingested Casilan® only (study I), after they had ingested labeled caffeine only (study II) and after they had also ingested both Casilan® and labeled caffeine (study III). The time courses of 13 C enrichments for the children, at different stages of the study (I-III), are shown in [Figure 1]. The curves differed according to the intake of a food supplement, i.e. the children had either ingested or not ingested Casilan® (a food supplement). After ingesting Casilan® only, the 13 C enrichments in the exhaled CO 2 were consistently low, fluctuating between ±10 -3 delta%, and yielded almost a plateau line [I in [Figure 1]]. This suggests a low level of 13 C in the Casilan® . The 13 C enrichments in the exhaled CO 2 of the children were identical after they had ingested labeled caffeine only and after they had ingested both Casilan® and labeled caffeine. The 13 C-enrichments followed a typical time course for CBT. The values increased gradually, reaching their peak values at about 60-75 min [II and III in [Figure 1]], followed by a gradual fall [II in [Figure 1]]. However, the 13 C enrichments approached a plateau after attaining the peak value in children who ingested both Casilan® and caffeine [III of [Figure 1]].
|Figure 1: Time course of 13C enrichment for normal healthy Nigerian children after ingesting Casilan® or labeled caffeine only, and after ingesting both Casilan® and caffeine|
Click here to view
The demographics and caffeine dose exhaled as 13 CO 2 over a 2-h period for each child, at different stages of the study (I-III), are shown in [Table 1]. The percentage caffeine dose in the cumulative 2-h 13 CO 2 was lower in the children after they ingested Casilan® only (I) compared with after they ingested labeled caffeine only (II) and after they ingested both Casilan® and labeled caffeine (III). The percentage caffeine dose in the cumulative 2-h 13 CO 2 was higher in seven children (four male, three female) after they had ingested both Casilan® and labeled caffeine compared with after they had ingested caffeine only. However, the remaining five children had contrasting results.
|Table 1: Clinical details and average percentage 13C-caffeine in the cumulative 2 hour CO2 output of healthy subjects without ingesting and after ingesting Casilan®|
Click here to view
The CBT of the children, after they ingested Casilan® or labeled caffeine only and after they ingested both Casilan® and caffeine, is presented in [Figure 2]. Data were expressed as mean ± SD. The mean values of the percentage caffeine dose exhaled over 2 h were identical after the children had ingested caffeine only (8.59 ± 1.10 δ6%/mg) and after they had ingested both Casilan® and labeled caffeine (8.58 ± 1.33 δ %/mg). There was no statistically significant difference in the mean values (P = 0.972) [Table 1]. However, after the children had ingested Casilan® only, the mean value of the percentage caffeine dose exhaled over 2 h (0.58 ± 1.39 δ %/mg) was significantly lower than the values after they had ingested caffeine only (P = 0.000) and after they had ingested both Casilan® and labeled caffeine (P = 0.000). The cumulative 13 CO 2 exhaled over a 2-h period is dependent on the 3-N-demethylation of caffeine. The very low level observed after the children had ingested Casilan® only and the identically high levels observed after the children had ingested caffeine only and after they had ingested both Casilan® and labeled caffeine would suggest that Casilan® , as a food supplement, did not significantly affect the CYP1A2 metabolic pathway.
|Figure 2: Caffeine breath test following the ingestion of Casilan®, labeled caffeine and both Casilan® and labeled caffeine|
Click here to view
After ingesting Casilan® and labeled caffeine, the percentage caffeine doses exhaled over 2 h by seven children were increased compared with after they ingested labeled caffeine only. Their mean values were 8.97 ± 1.00 δ%/mg and 8.21 ± 0.95 δ%/mg, respectively, and the difference in the mean values was not statistically significant (P = 0.054). However, the percentage caffeine doses exhaled over 2 h by the remaining five children were decreased after ingesting Casilan® and labeled caffeine compared with after they ingested labeled caffeine only. Their mean values were 8.02 ± 1.63 δ%/mg and 9.12 ± 1.18 δ%/mg, respectively. The difference in the mean values was also not statistically significant (P = 0.069). These results further suggest that Casilan® has no significant effect on CYP1A2 metabolic activities.
There was no significant correlation between age (r = -0.396, P = 0.202), weight (r = -0.287, P = 0.366), height (r = -0.309, P = 0.329) and cumulative percent of labeled caffeine dose recovered in the 2-h CO 2 exhaled after ingesting Casilan® only. No significant correlation was also observed between age (r = -0.018, P = 0.957), weight (r = 0.117, P = 0.718), height (r = 0.330, P = 0.295) and cumulative percent of labeled caffeine dose recovered in the 2-h CO 2 exhaled after ingesting labeled caffeine only. Similarly, no significant correlation was observed between age (r = 0.453, P = 0.140), weight (r = -0.372, P = 0.234), height (r = -0.109, P = 0.736) and cumulative percent of labeled caffeine dose recovered in the 2-h CO 2 exhaled after ingesting both Casilan® and labeled caffeine.
| Discussion|| |
This study is the first of its kind to evaluate the effect of Casilan® , a food supplement, on caffeine metabolism. It is part of a large study aimed at using a noninvasive method, particularly the CBT, to assess the effect of malnutrition on caffeine metabolism. Fasting is very essential in CBT studies, but may not be ethically feasible in malnourished children. There is an unfulfilled clinical need for a food supplement to be administered to malnourished children undergoing CBT. There has never been a search for a safe, reliable and quantitative food supplement that will yield reliable CBT data in malnourished children probably because CBT has not been applied to the study of effect of malnutrition on drug disposition in children. 
The results from the present study showed that Casilan® is a safe and reliable food supplement for children undergoing CBT. Our data indicate that (1) Casilan® was administered easily and safely to children, (2) caffeine metabolism was not significantly influenced by Casilan® ingestion as demonstrated by the pattern of time course of 13 C enrichments in breath CO 2 after the children ingested either Casilan® or labeled caffeine and after they ingested both Casilan® and labeled caffeine, (3) the 13 C enrichment, after the children ingested Casilan® only, remained stable at very low levels, yielding almost a flat plot, (4) peak values of the 13 C enrichment after the children ingested caffeine only and after they ingested both Casilan® and labeled caffeine were attainable at an average time of 60-75 min, followed by a gradual decline or a sustained plateau and (5) the mean value of the percentage cumulative caffeine doses exhaled by the children over 2 h after they ingested both Casilan® and labeled caffeine was identical to the mean value obtained after they ingested labeled caffeine only, and the difference in the mean values was not statistically significant.
The time courses of caffeine metabolism after the children had ingested labeled caffeine only and after they had ingested both Casilan® and caffeine are in general agreement with previously published breath test studies in children.  Park et al.  have shown that the time to peak plasma caffeine concentrations as well as peak caffeine level after oral administration was 1 h for normal adult control patients. Different developmental patterns have been identified for CYP-450 activities in children. The fetal liver has between 30% and 60% of adult total cytochrome P-450 values, and approaches adults values by 10 years of age.  Given the age range (3-8 years) of the children studied, their CYP1A2 quantity and activities are likely to be slightly lower than those of the adults. This may explain the slight variation in time (60-75 min) to peak labeled caffeine levels observed in our study. Studies have also shown that optimal correlation between the plasma clearance of caffeine in infants, older children and adults, and the cumulative excretion of 13 CO 2 was at 2 h.  The fact that the time to peak caffeine levels was not significantly different after the children had ingested labeled caffeine only and after they had ingested both Casilan® and caffeine may suggest that Casilan® did not alter the CYP1A2 activity involved in the hepatic metabolism of caffeine.
Carbohydrate diets are rich in 13 C  and are likely to increase the exhaled 13 CO 2 during CBT. Casilan® , being very low in fat and carbohydrate, is unlikely to have contributed to the slightly higher levels of 13 C enrichment and the cumulative 13 CO 2 exhaled over the 2-h study period observed in the seven children after they ingested Casilan® and caffeine, compared with after they ingested caffeine only. Ingestion of Casilan® will likely increase the basal metabolic rate with a corresponding increase in endogenous 13 CO 2 production in the subjects. Given the low quantity of Casilan® (one-twelfth of the RDA) administered to the subjects, the endogenous 13 CO 2 production is likely to be minimal and very unlikely to influence the levels of 13 C-enrichments and the cumulative 13 CO 2 exhaled after the subjects ingested Casilan® .
The 13 C recovered in the exhaled 13 CO 2 of five children, over the 2-h study period, was slightly lower after they ingested Casilan® and caffeine than after they ingested caffeine only. Compared with the seven children with contrasting results, the difference in the 13 C recovery may be explained by physiological effects. The lower 13 C recovery in the five children may indicate that 13 C was partly lost via a route other than the pulmonary route. It has been previously reported that 1-2% of total CO 2 excretion was lost across the skin.  The imperceptible lost may vary from one child to another. The recovery of 13 C may also be reduced by 13 C fixation in the body pools and constituents with a slow turnover such as bone, skeletal tissue and fat, and, to a lesser part, excretion via urine and feces.  The latter was estimated to be smaller than 6% in bulls. 
Rigorous stability testing has not yet been performed with the CBT, particularly in tropical African countries. However, we can extrapolate the stability data on 13 C-urea breath samples,  which are essentially the same as the breath samples in this study, suggesting that CBT samples from our subjects are similarly stable. The present study is likely the first of its kind to extend CBT to children in Africa. CBT samples were collected and stored for about 12 weeks before being transported to the United Kingdom for analysis. The results from our study are reliable and suggest that the CBT samples were stable over the period of storage in Nigeria. This is however a significant advantage of CBT over other quantitative assays.
Previous CBT in children and adults have shown that caffeine metabolism, expressed as a 2-h cumulative exhalation of 13 CO 2 , is not influenced by age , and gender , in older children, similar to the age group we studied. However, we were unable to draw a firm conclusion with regard to the influence of age and gender on caffeine metabolism in children after they ingested Casilan® only and after they ingested both Casilan® and labeled caffeine due to the few subjects involved in the study.
Intra - and interindividual variations in CYP1A2 activity have been reported.  About 35-75% of the interindividual variability in CYP1A2 activity is due to genetic factors.  The interindividual differences are likely to influence the metabolism of 13 C as well as explain the variation in the cumulative 13 C-dose recovered in the 2-h CO 2 exhaled by each subject. It is hoped that future studies would explore the genetic roles of CYP1A2 in 13 C metabolism. However, the use of the same individual as subjects and controls in this study has eliminated possible bias from interindividual variation in CYP1A2 activity that characterized previous CBT. Similarly, studying the subjects at the same time of the day (09:00 h)also has helped eliminate bias due to intraindividual genetic variation.
In conclusion, the present study confirms that Casilan® is a safe, simple and quantitative food supplement for overnight-fasted children undergoing oral CBT. The reliability of the yielded data suggests that Casilan® may be used to address unethical issues surrounding fasting of nutritionally deficient children undergoing CBT. This pilot study, in a few number of children, is considered as the basis for validation in a larger study.
| References|| |
|1.||Risby TH, Solga SF. Current status of clinical breath analysis. Appl Phys B 2006;85:421-6. |
|2.||Braden B, Lembcke B, Kuker W, Caspary WF. 13 C-breath tests: Current state of the art and future directions. Dig Liver Dis 2007;39:795-805. |
|3.||Parker AC, Pritchard T, Preston T, Smyth RL, Choonara I. Enhanced drug metabolism in young children with cystic fibrosis. Arch Dis Child 1997;77:239-41. |
|4.||Wetzel K, Fischer H. 13 C - breath tests in medical research and clinical diagnosis. Available at http://www.fan-gmbh.de/docs/13c-breathtests.pdf (Accessed 7th April, 2011). |
|5.||Schoeller DA, Schneider JF, Solomons NW, Watkins JB, Klein PD. Clinical diagnosis with stable isotope 13 C in CO 2 breath tests: Methodology and fundamental considerations. J Lab Clin Med 1977;90:412-21. |
|6.||Lambert GH, Kotake AN, Schoeller D. The CO 2 breath tests as monitors of cytochrome P450 dependent mixed function monooxygenase system. Prog Clin Biol Res 1983;135:119-45. |
|7.||Slater C, Preston T, Weaver LT. Is there an advantage in normalising the results of the Helicobacter pylori [ 13 C] urea breath test for CO 2 production in children? Isotopes Environ Health Stud 2004;40:89-98. |
|8.||Shreeve VW, Cerasi E, Luft R. Metabolism of [2- 14 C] pyruvate in normal, acromegalic and HGH-treated human subjects. Acta Endocrinol (Copenh) 1970;65:155-69. |
|9.||Haycock G, Schwartz G, Wisotsky G. Geometric method for measuring body surface area: A height-weight formula validated in infants, children and adults. J Pediatr 1978;93:62-6. |
|10.||Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Human Nutr Clin Nutr 1985;39:5-41. |
|11.||IDECG. The Doubly-labelled water method for measuring energy expenditure: Technical recommendations for use in humans. Vienna: IEA; 1990. |
|12.||Slater C, Preston T, Weaver LT. Comparison of accuracy and precision of heart rate calibration methods to estimate total carbon dioxide production during 13 C-breath tests. Eur J Clin Nutr 2006;60:69-76. |
|13.||British national formulary for children. United Kingdom: BMJ Publishing Group Ltd, RPS Publishing, and RCPCH Publications Ltd; 2006. |
|14.||WHO Child Growth Standards: Methods and development: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and mass index-for-age. World Health Organization, 2005. Available on www.who.int/childgrowth/standards/Techical_report.pdf (Accessed May, 2011). |
|15.||de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007;85:660-7. |
|16.||Park GJ, Katelaris PH, Jones DB, Seow F, Le Couteur DG, Ngu MC. Validity of the 13 C-Caffeine breath test as a non-invasive, quantitative test of liver function. Hepatology 2003;38:1227-36. |
|17.||National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press, 1989. |
|18.||Craig H. Isotopic standards for carbon and oxygen and corrections factors for mass -spectrometric analysis of carbon dioxide. Geochim Cosmochim Acta 1957;12:133-49. |
|19.||Preston T, McMillan DC. Rapid sample throughput for biomedical stable isotope tracer studies. Biomed Environ Mass Spectrom 1988;16:229-35. |
|20.||Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetic studies in children with protein-energy malnutrition. Eur J Clin Pharmacol 2010;66:217-22. |
|21.||Rating D, Langhans CD. Breath tests: Concepts, application and limitations. Eur J Pediatr 1997;156 (Suppl 1):S18-23. |
|22.||de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A. Ontogeny and drug disposition. Clin Pharmacokinet 1999:37:485-505. |
|23.||Pons G, Blais JC, Rey E, Plissonnier M, Richard MO, Carrier O, et al. Maturation of caffeine N-demethylation in infancy: A study using the 13 CO 2 breath test. Pediatr Res 1988;23:632-6. |
|24.||Alkalay I, Suetsugu S, Constantine H, Stein M. Carbon dioxide elimination across human skin. Am J Physiol 1971;220:1434-6. |
|25.||Elia M. Estimation of short-term energy expenditure by the labelled bicarbonate method. In: Whitehead RG, Prentice A, editors. New techniques in nutritional research. New York, NY: Academic Press; 1991. p. 207-27. |
|26.||Junghans P, Voigt J, Jentsch W, Metges CC, Derno M. The 13 C bicarbonate dilution technique to determine energy expenditure in young bulls validated by indirect calorimetry. Livest Sci 2007;110:280-7. |
|27.||Colaiocco-Ferrante L, Papponetti M, Marcuccitti J, Neri M, Festi D. 13 C-urea breath test for helicobacter pylori infection: Stability of samples over time. Scand J Gastroenterol 1999;34:942-3. |
|28.||Webster E, McIntyre J, Choonara I, Preston T. The caffeine breath test and CYP1A2 activity in children. Paediatr Perinat Drug Ther 2002;5:28-33. |
|29.||Lambert GH, Schoeller DA, Katoke AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther 1986;9:375-88. |
|30.||Dailly E, Urien S, Chanut E, Claudel B, Guerra N, Femandez C, et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter - and intra-individual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Pyschiatry 2002;26:699-703. |
|31.||Ismael M, Del Carpio CA. Elucidate the origin of CYP flexible structural variation using molecular dynamics calculation. J Toxicol Environ Health Sci 2011;3:335-41. |
[Figure 1], [Figure 2]